Status:
WITHDRAWN
Melatonin on Clock Genes in Parkinson's Disease
Lead Sponsor:
Instituto Mexicano del Seguro Social
Conditions:
Parkinson Disease
Eligibility:
All Genders
20+ years
Phase:
PHASE2
PHASE3
Brief Summary
Parkinson's disease (PD) is the second most important neurodegenerative disease that affects about 2% of the population over 60 years of age. About 40% of the Mexican population with PD suffer from sl...
Detailed Description
A controlled, double-blind, randomized clinical trial will be carried out in 58 patients with a diagnosis of PD. Twenty-nine patients will receive Melatonin and 29 placebo. A blood sample will be take...
Eligibility Criteria
Inclusion
- Patients with diagnosis of PD in stages 1-3 of the classification by stages of Hoehn \& Yahr
- Go with a companion to the appointments
- Patients who agree to participate in the study and sign the Informed Consent letter
Exclusion
- Patients with movement disorder other than PD
- Prior pallidotomy, thalamotomy or deep brain stimulation
- Pregnant
- Patients who consume alcohol or coffee
- Patients who consume an antioxidant supplement
Key Trial Info
Start Date :
May 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2022
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04287543
Start Date
May 1 2021
End Date
August 1 2022
Last Update
August 4 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Instituto Mexicano del Seguro Social
Guadalajara, Jalisco, Mexico, 44340